Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

Lactobacillus acidophilus L-92 and Reduced Inflammation

Research synthesisLow evidenceSmall effect9 studies · 9 beneficial · 0 neutral · 0 harmful

Across 9 studies on *Lactobacillus acidophilus* L-92 and reduced inflammation, all reported beneficial effects, with effect sizes predominantly small to moderate. The strongest evidence comes from a large meta-analysis (n=3,390) showing small beneficial reductions in high-sensitivity C-reactive protein, TNF-α, and lipopolysaccharides in subjects with type 2 diabetes, and one small RCT (n=100) reported statistically significant moderate reductions in inflammatory markers (ESR, CRP) in underweight participants. Most studies were reviews, and specific dose ranges and durations were not consistently reported.

  • Studied populations: subjects with type 2 diabetes, underweight individuals, populations with environmental sensitivity illnesses, older adults with sarcopenic obesity and related conditions, athletes

Caveats: Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (beneficial results are more likely to be published or indexed). Only 1 of 9 studies reported a statistically significant finding, and most studies were reviews rather than primary intervention trials, limiting the certainty of the effect. Doses, study durations, and specific forms of *Lactobacillus acidophilus* L-92 were not reported in the included studies, making it impossible to identify an effective or standardized regimen.

Generated May 12, 2026
9 of 9 papers
Back to top